Therapeutic potential of KCa3.1 blockers: recent advances and promising trends

Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis

(2010) L. Di et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The K+channels KCa3.1 and Kv1.3 as novel targets for asthma therapy

(2009) Peter Bradding et al.   BRITISH JOURNAL OF PHARMACOLOGY

Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery

(2009) Ivica Grgic et al.   BRITISH JOURNAL OF PHARMACOLOGY

Intermediate conductance Ca2+-activated potassium channel (KCa3.1) in the inner mitochondrial membrane of human colon cancer cells

(2009) Umberto De Marchi et al.   CELL CALCIUM

Genetic Deficit of SK3 and IK1 Channels Disrupts the Endothelium-Derived Hyperpolarizing Factor Vasodilator Pathway and Causes Hypertension

(2009) Sebastian Brähler et al.   CIRCULATION

Enhanced Glucose Tolerance by SK4 Channel Inhibition in Pancreatic  -Cells

(2009) M. Dufer et al.   DIABETES

Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia

(2009) Kenneth I Ataga et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels

(2009) I. Grgic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of T-Lymphocyte KCa3.1 and Kv1.3 Channels as Novel Immunosuppression Strategy to Prevent Kidney Allograft Rejection

(2009) I. Grgic et al.   TRANSPLANTATION PROCEEDINGS

Local Delivery of the K Ca 3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis

(2008) D.L. Tharp et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

(2008) K. I. Ataga et al.   BLOOD

Modulation of Endothelial Cell K Ca 3.1 Channels During Endothelium-Derived Hyperpolarizing Factor Signaling in Mesenteric Resistance Arteries

(2008) Kim A. Dora et al.   CIRCULATION RESEARCH

KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?

(2008) Chuan-Chu Chou et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans

(2008) Kazuyoshi Toyama et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease

(2008) Grant A. McNaughton-Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease

(2008) Mamdouh Albaqumi et al.   KIDNEY INTERNATIONAL

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

(2008) A. Sankaranarayanan et al.   MOLECULAR PHARMACOLOGY

Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly

(2008) Ivica Grgic et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1

(2008) S. Srivastava et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional architecture of inositol 1,4,5-trisphosphate signaling in restricted spaces of myoendothelial projections

(2008) J. Ledoux et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA